Genmab — Juni 2019
-
Celgene viser kliniske data for arvtager til super-blockbuster mod knoglemarvskræft
Amerikanske Celgene har fremlagt positive kliniske data for et nyt immunmodulerende middel til behandling af knoglemarvskræft, som ser ud til at kunne hjælpe patienter, når behandling med Genmabs Darzalex eller selskabets egen storsællert Revlimid fejler.
(medwatch.dk)
-
@Sukkeralf are they talking about Iberdomide there?
-
Mens vi venter......et eller andet må være under opsejling....underlig udvikling i dag....
-
Ok, thks. i think that is for Dara refractory for now, and it has synergy with Dara , the Dara combo is already in trial https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.8006
-
Jeg er overbevist om, at CELG presser dara ved at hæve prisen på Revlimid hele tiden. Vi mangler en slagkraftig kombination, hvor Revlimid eller Pomalyst ikke indgår. Ellers må vi nok have lidt tålmodighed med gennemslaget i first line til patentudløb 2022/23 eller før med Dara-sc
-
Pensionisten - kan du ikke brokke dig lidt, gerne de samme gloser som i går, hvor det virkede positivt på kursen
-
"Currently, JNJ-372 is trying to use combination therapy with a variety of medications, including Lazertinib.
In particular, Lazertinib has been evaluated as having a strong effect on patients with brain cancer as it was able to cross the blood-brain barrier that JNJ-372 had failed to cross. " http://www.koreabiomed.com/news/articleView.html?idxno=5861
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind